Loading clinical trials...

COMPLETEDPHASE2

Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

NCT00232999•Teva Branded Pharmaceutical Products R&D, Inc.

Summary

This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Mild stable allergic asthma
•Positive skin-prick test to at least one common aeroallergen
•Positive methacholine challenge
•Positive allergen-induced early- and late-phase airway bronchoconstriction
•General good health

Exclusion Criteria

•Lung diseases other than mild allergic asthma
•History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease
•Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium
•Use of tobacco products within one year starting study or smoking history \>10 pack years
•If female, pregnant or lactating or have positive pregnancy test at screening

Locations (3)

Department of Medicine, McMaster University

Hamilton, Ontario, Canada

Centre de cardiology et de pneumologie de l'Universite Laval

Sainte-Foy (Quebec City), Quebec, Canada

University of Saskatchewan

Saskatoon, Saskatchewan, Canada

Key Dates

Start Date

October 1, 2005

Primary Completion Date

December 1, 2005

Completion Date

January 1, 2006

Last Updated

November 12, 2021

Enrollment

ACTUAL participants

Conditions

Asthma

Interventions

Nebulized IVX-0142

DRUG

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173

Asthma

View study

RECRUITINGNA

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Asthma ExacerbationsBiomarkers / Blood+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 12, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma